Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antineoplaston A10/antineoplaston As2-1 - Burzynski Research Institute

Next Previous
X
Search
Drug Profile

Antineoplaston A10/antineoplaston As2-1 - Burzynski Research Institute

Alternative Names: A10; A10 I; ANP; Antineoplastons A10/AS2-1; Antineoplastons therapy; AS2-1; Astugenal (AS2-1); Atengenal (A10); Atengenal + Astugenal; NSC-620261; NSC-648539

Latest Information Update: 17 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Burzynski Research Institute
  • Class Amino acids; Antineoplastics; Antineoplastons; Benzeneacetamides; Phenylacetates; Piperidones
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; DNA intercalators; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anaplastic astrocytoma; Glioma
  • No development reported Colorectal cancer

Most Recent Events

  • 08 Mar 2022 Burzynski Research Institute suspended enrollments in a phase-II clinical trial in Glioma (In infants, In children, In adolescents, In adults, In the elderly) in USA (IV), due to clinical hold (NCT02742883)
  • 01 Apr 2017 Burzynski Research Institute terminated a phase II trial due to slow accrual in Glioma (Second-line therapy or greater, In children, In adolescents) in USA (IV) (NCT00003476)
  • 07 Dec 2016 Discontinued - Phase-II for Glioma (Metastatic disease, Adjuvant therapy) in USA (IV) (NCT02988726)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top